

LIST OF FIGURES

Figure No.	Caption	Page No.
1	Major complications involved in diabetes	2
2	Current pharmacotherapies of diabetes	3
3	Structure of the phosphate-binding loop (P-loop)	10
4	General mechanism of catalysis of PTPs	11
5	Classification and substrate specificity of PTPs	12
6	Simplified schematic of the insulin signaling pathway	13
7	Crystal structures along the pathway of the reaction catalyzed by PTP1B.	16
8	Docking pose of compound 5 in the active site of PTP1B	53
9	Docking pose of compound 60 , 90 and 128 in the active site of PTP1B	54
10	Enzyme kinetic properties of compound 5	120
11	Graph of V_{max} vs I of compound 5	121
12	Double reciprocal plot of compound 5	121
13	Plot of inhibitory concentration [I] to K_m of 5	122
14	Enzyme kinetic properties of compound 60	122
15	Graph of V_{max} vs I of compound 60	123
16	Double reciprocal plot of compound 60	124
17	Enzyme kinetic properties of compound 90	124
18	Graph of V_{max} vs I of compound 90	125
19	Double reciprocal plot of compound 90	126
20	Plot of inhibitory concentration [I] to K_m of 90	126

LIST OF TABLES

Table No.	Caption	Page No.
1	Current therapeutic agents for Type-2 diabetes	4-5
2	Emerging Anti-diabetes Targets	6-8
3	Glide score of most potent PTP1B inhibitor	53
4	Selectivity profile of compound 5 , 60 , 63 , 79 , 90 and 92	55
5	Substitutions	58-59
6	List of substituted aldehydes	98
7	Set wise distribution of compounds	112
8	<i>In vitro</i> activity of set-I compounds against human PTP1B	113
9	<i>In vitro</i> activity of set-II compounds against human PTP1B	114
10	<i>In vitro</i> activity of set-III compounds against human PTP1B	115
11	<i>In vitro</i> activity of compounds against CDC25B	116
12	<i>In vitro</i> activity of compounds against LAR	117
13	<i>In vitro</i> activity of compounds against SHP-1	118
14	<i>In vitro</i> activity of compounds against TCPTP	119
15	V _{max} (mOD/Min) of compound 5	120
16	V _{max} (mOD/Min) of compound 60	123
17	V _{max} (mOD/Min) of compound 90	125
18	Physical and IR data of intermediates A1 to A53	130-131
19	Physical and IR data of intermediates B1 to B53	150-151
20	Physical and IR data of intermediates C1 to C53	152-153

LIST OF SYNTHETIC SCHEME

Scheme No.	Caption	Page No.
I & II	Synthesis of substituted 2-Imino-thiazolidin-4-ones (A1-A53)	57
III	Synthesis of derivatives of {[4-oxo-2-(imino)-1,3-thiazolidin-5-ylidene] methyl}benzoic acids (1-48)	60
IV	Synthesis of substituted 5-(4-hydroxy-benzylidene)-2-imino-thiazolidin-4-ones (B1-B53)	79
V	Synthesis of substituted [(4-oxo-2-imino-thiazolidin-5-ylidenemethyl)-phenoxy]-acetic acid ethyl esters (C1-C53)	80
VI	Synthesis of derivatives ([4-oxo-2-(imino)-1,3-thiazolidin-5-ylidene]methyl}ph-enoxy)acetic acids (49-96)	80
VII	Synthesis of 4-(4-oxo-3-phenyl-thiazolidin-2-ylideneamino)-benzoic acid (D)	97
VIII	Synthesis of derivatives of 4-(4-oxo-3-phenyl-thiazolidin-2-ylideneamino)-benzoic acids (97-114)	97
IX	Synthesis of [4-(4-oxo-3-phenyl-thiazolidin-2-ylideneamino)-phenyl]-acetic acid (E)	105
X	Synthesis of derivatives of [4-(4-oxo-3-phenyl-thiazolidin-2-ylideneamino)-phenyl]-acetic acids (115-132)	105